Please login to the form below

Not currently logged in

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

J&J’s targeted bladder cancer treatment gets US approval

J&J’s targeted bladder cancer treatment gets US approval

Balversa is first FGFR inhibitor. Johnson &Johnson’s highly anticipated bladder cancer drug Balversa has been approved in the US, becoming the first personalised treatment targeting a certain type of genetic ... J&J was awarded that status following

Latest news

More from news
Approximately 0 fully matching, plus 147 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company -  remaining 90%. 9

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... 282. Carna Biosciences/ ProNAi Therapeutics. Licence. $0.9m

  • Pharma deals in September 2015 Pharma deals in September 2015

    Purdue licensed VM Pharma's allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor programme for chronic pain. ... Collaboration - public private partnership. 220. VM Pharma. Purdue Pharma. VM902A a signalling protein tropomyosin receptor

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...